Kilter Group’s Myriad Genetics MYGN Stock Holding History

Kilter Group’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-72	Closed	-$521	–	1461
2025 Q3	$521	Hold	72	–	–	﹤0.01%	1049
2025 Q2	$383	Buy	+72	New	+$425	﹤0.01%	1027

Other funds holding MYGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GCM

Glenview Capital Management New York $5.49B AUM 46.89% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Kilter Group's MYGN Position: Q4 2025 in Review

Kilter Group sold out of Myriad Genetics (MYGN) in Q4 2025, closing a stake of 72 shares — an estimated $521 sold.

Kilter Group first reported a position in MYGN in Q2 2025 and held it in 2 quarters. The position peaked at $521 in Q3 2025. 221 funds tracked by Wall St. Rank hold MYGN as of Q4 2025.

Kilter Group reported no remaining Myriad Genetics position as of Q4 2025 after selling out during the quarter.
Kilter Group sold 72 Myriad Genetics shares in Q4 2025, an estimated $521.
Kilter Group first reported a position in Myriad Genetics in Q2 2025 and held it in 2 quarters.
Kilter Group's Myriad Genetics position peaked at $521 in Q3 2025.
221 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2025.

Based on Kilter Group's 13F filing for Q4 2025, filed 13 Feb 2026.